From December 4-9, 2023, the 22nd ICASA was held in Zimbabwe, with over 4,000 participants from over 80 countries around the world discussing AIDS, Hepatitis and Sexually Transmitted Infections (STIs). Wondfo exhibited products prequalified by WHO, and in this way, we actively facilitate global health and contribute China's strength to build a community of human health.
 

 

In Africa's Largest Forum, Wondfo Biotech Receives Recognition

As the most influential conference on HIV/STIs in Africa, the biennial International Conference on AIDS and Sexually Transmitted Infections in Africa (ICASA) is also the major and largest forum in Africa. It brings together key stakeholders in HIV, Sexually Transmitted Infections (STIs) and infectious diseases, including Heads of State and Government, Ministers of Health, national HIV program staff, advocates, scientists, service providers, civil society representatives and many others. This is a critical meeting discussing HIV, hepatitis and STIs.

During ICASA 2023, Wondfo exhibited two diagnostic products that have been prequalified by WHO: One Step HIV 1/2 Whole Blood/Serum/Plasma Test and Wondfo HIV Self-Test, which made impressions. International organizations and local NGOs in Africa affirmed the performance of the products and appreciated Wondfo's efforts for global public health.

The two products exhibited adopt colloidal gold immunochromatography method, which does not require any instrument and features short testing time, convenient operation and high testing efficiency. With only 3-step operation, accurate results are delivered in 15 minutes, which is convenient for individuals and families to carry out auxiliary diagnosis and daily monitoring of HIV. It can also be applied in healthcare institutions, reduce the burden on healthcare staff and effectively improve the efficiency and accessibility of HIV testing services.

Pilot Study Shows: Reliable Performance
Wider Application is Recommended

Since 2012, Wondfo has provided services to more than 40 African countries, including Kenya, Ethiopia and Nigeria. The products and services have obtained appreciations. Wondfo has been working with local medical institutions and public welfare organizations to carry out free community healthcare, and exploring medical cooperation through technical assistance, industry-academia-research cooperation, etc.

During the conference, a report on the pilot study of HIV self-testing (HIVST) was released. The study was jointly conducted by CHAI, an international organization, and the Ministry of Health of Uganda. The researchers distributed Wondfo HIV self-testing to 5,431 people from 20 hospitals in April 2023 and conducted an acceptability survey. The study shows that Wondfo HIV self-testing has reliable performance and good acceptability. The report recommends Uganda's Ministry of Health for wider application of Wondfo HIV self-testing for AIDS testing.

In 2022, MedAccess, the Clinton Health Access Initiative and Wondfo announced an agreement to make Wondfo’s HIV self-test available for $1. The price makes Wondfo’s test the most affordable World Health Organization prequalified HIV self-test on the market. In October 2023, Uganda became the first country to adopt HIV self-tests procured under the terms of MedAccess’ volume guarantee to Wondfo, adding Wondfo’s HIV Self-Testing to the country’s HIV self-testing portfolio.

Racing for Life, Wondfo has always been devoted to the facilitation of global health, safeguarding the life and health of the world with practical actions, contributing China's strength to the construction of a human health community, and striving to realize the vision of "Make biology technology benefit the public".